Impact of Salvage Therapy on Outcomes in Patients with Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma Prior to Autologous or Allogeneic Stem Cell Transplant Read more
Phase 1, Open-Label Study of Autologous SIRPA-low Macrophages (SIRPant-M) a cellular therapeutic product Administered by Intratumoral Injection Alone or in Combination with Focal External-Beam Radiotherapy in Participants with Relapsed or Refractory Non-Hodgkin’s Lymphoma Read more
TP53-Altered Aggressive Large B-Cell Lymphoma Outcomes by Treatment Modality: A Multicenter Retrospective Review Read more
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) Read more
An Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy. Read more
Role of Donor Cell Chimerism in Predicting Relapse Post-Transplant in Patients with Hematologic Malignancies Read more
Incidence of Engraftment Syndrome in Classical Hodgkin Lymphoma after Checkpoint Inhibitors: A Retrospective Analysis Read more
Transcriptional Profiles of CD19 Chimeric Antigen Receptor (CAR) T-cells that Induce Durable Remission in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Read more
